Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael ...

Three-quarters of those surveyed said the program’s resources helped reduce unwanted physical side effects, and more than 80% said it lessened at least one aspect of financial stress. Overall, 85% ...

Oppenheimer upgraded Dyne Therapeutics (DYN) on Wednesday, citing a positive read-through from data that Novartis’ (NVS) buyout target Avidity Biosciences (RNA) is set to release this year from a late ...

Dec 10 (Reuters) - Pfizer will ‌cut ​over 200 jobs ‌in Switzerland as part of its ​multi-year cost reduction program, ...

Expression Therapeutics Inc., a clinical-stage biopharmaceutical company developing next-generation cellular therapies, has appointed David F. Townson, Ph.D., as Chief Executive Officer, effective ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...

New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...

UnitedXR Europe also will host the fabulous XR Awards Gala later today, recognizing innovation and excellence in VR, AR and XR. The XR Awards are the result of a strategic merger between AIXR's XR ...

The collaboration pairs Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s deep expertise in immuno-dermatology to identify, validate, and advance ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...